Skip to content

    NGL Fine-Chem Limited

    NGLFINE
    Healthcare·26 May 2025
    Management Summary

    NGL Fine Chem reported a challenging Q4 FY25 with significant margin compression and a 49% decline in FY25 PAT, primarily due to heightened competition, subdued realizations, and geopolitical issues. Despite these headwinds, the company successfully commercialized Phase 1 of its capex project and remains committed to strategic initiatives, including regulated market entry and process reengineering, with meaningful sales from new capacities expected from FY27.

    Highlights

    5

    • FY25 revenue from operations increased by 8.7% YoY to INR368.26 crores.

    • Q4 FY25 revenue from operations saw a sequential increase of 6.6% to INR94.97 crores.

    • Successful commercialization of Phase 1 of the capex project, with validation batches underway.

    • Secured 3 CEPs and 5 DMF filings, with 5 customers onboarded in the EU market.

    • Fluralaner, a recently off-patent product, is doing well, with NGL Fine Chem being the sole Indian manufacturer.

    Concerns

    5

    • Q4 FY25 EBITDA declined by 60% YoY to INR6.32 crores, with margin contracting by 921 bps YoY to 6.7%.

    • FY25 PAT decreased by 49% YoY to INR21.12 crores.

    • Heightened competition, subdued realizations, and increased operating expenses led to margin compression.

    • Geopolitical tensions (India-Pakistan conflict) and currency availability issues in African markets significantly impacted business, leading to zero sales to Pakistan this year (down from INR15 crores).

    • Anticipated a modest cost overrun for the capex project, with total outlay now estimated at INR160 crores.

    What Changed2

    vs Q2 FY26

    Guidance items10 → 9 (-1)Risks discussed4 → 5 (+1)
    Key financials

    Metrics

    9

    Periods

    2

    Q4 FY25

    4
    • Revenue
      ₹94.97 Cr
      YoY-4.8%QoQ+6.6%
    • EBITDA
      ₹6.32 Cr
      YoY-60%QoQ+24%
    • EBITDA Margin
      6.7%
      YoY-9.2%QoQ+0.9%
    • PAT
      ₹0.54 Cr

    FY25

    5
    • Revenue
      ₹368.26 Cr
      YoY+8.7%
    • EBITDA
      ₹33.87 Cr
    • EBITDA Margin
      9.2%
      YoY-6.5%
    • PAT
      ₹21.12 Cr
      YoY-49%
    • Volume Growth
      20%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹160 crores

    raised — modest cost overrun · 60-40 debt-equity structure

    Debt

    Debt disclosed

    Guidance & targets

    9
    CategoryTargetPriority
    Capex
    Capex Project Completion
    Q3 of current financial year
    		High
    Sales
    Meaningful Sales from New Capex
    End of FY '27 onwards
    		High
    Sales
    EU Sales from Existing Plant
    INR25-30 crores
    		Medium
    Sales
    Pakistan Sales
    0
    		High
    Regulatory
    US FDA Filing
    End of this calendar year (Oct-Dec quarter)
    		High
    Regulatory
    US FDA Approval
    2027
    		Medium
    Profitability
    Additional Margin from Regulated Market
    10-15%
    		Medium
    Operating Expenses
    Fixed Cost from Phase 1 New Plant
    INR40-50 lakhs per month
    		High
    Asset Turnover
    Asset Turn for New Investment
    1.6x-1.7x
    		Medium

    Process Reengineering Impact on Margins

    Within 3-6 months
    CurrentMargins compressed due to competition and realizations
    TargetImproved margins due to process reengineering

    Why it matters

    Management is actively working on cost and process improvements to restore margins, which is crucial for profitability.

    So, there is a lot of introspection going on being done -- undertaken by us to get a return back to margins in a better way. And these are things with cycles which will probably take a few months. But we are hopeful that in the next 3 to 6 months, we will be able to implement significant process engineering and to drive better margins.

    How to verify

    key_financials.metrics[label='EBITDA Margin']

    Risks & concerns

    5
    RiskSeverity

    Heightened Competition & Subdued Realizations

    Primary reason for margin compression, driven by overcapacity in the industry from both India and China, leading to lower prices across the product range. — Management acknowledged

    high

    Geopolitical Tensions & Currency Issues

    India-Pakistan conflict led to zero sales to Pakistan this year (down from INR15 crores). African markets face slow realizations due to lack of USD for imports. — Management acknowledged

    medium

    Duration of Industry Down Cycle

    Management cannot predict how long the current overcapacity and pricing pressure will last, expecting it to take a couple of years for capacity rationalization. — Management acknowledged

    medium

    Capex Cost Overrun

    A modest cost overrun was announced for the capex project, increasing the total outlay to INR160 crores. — Management acknowledged

    low

    Short-term Margin Pressure from New Capacity

    Management expects 6-8 quarters of pressure on margins due to higher operating costs from the new plant before meaningful sales contribute from FY27 onwards. — Management acknowledged

    medium

    Q&A highlights

    8

    “The question as to how long this cycle will last is actually something which we are not able to really predict. But there is a substantial overcapacity created in the industry. And until that gets absorbed, we will continue to face price pressures and therefore, pressure on our margins.”

    Analyst questioned the timeline for returning to normalized double-digit margins, and management indicated uncertainty due to industry overcapacity.

    asked by Ankit Minocha

    2 min read6 chapters

    Detailed Narrative

    01

    Financial Performance Overview

    NGL Fine Chem reported a challenging Q4 FY25, with revenue from operations at INR94.97 crores, a sequential increase of 6.6% but a 4.8% decline year-on-year. For the full year FY25, revenue grew 8.7% to INR368.26 crores. EBITDA for Q4 FY25 stood at INR6.32 crores, down 60% YoY, with the EBITDA margin contracting by 921 basis points YoY to 6.7%. Full-year FY25 PAT declined 49% to INR21.12 crores, reflecting significant margin compression.

    02

    Operational Challenges & Market Dynamics

    The company faced a challenging operating environment due to subdued demand and heightened competition, exacerbated by new capacities entering the market both in India and internationally. This led to a supply-demand mismatch, lower prices, and pressure on realizations across the product range. Management noted substantial overcapacity in the API business, with China holding an 80-85% market share, contributing significantly to competitive intensity.

    03

    Capex Project Update & Strategic Initiatives

    Phase 1 of the capex project, including clean rooms, was successfully commercialized, with validation batches underway. The company remains committed to completing Phase 2 by Q3 of the current financial year (FY26), though a modest cost overrun increased the total outlay to INR160 crores. Meaningful sales contributions from this new capacity are expected from end of FY27 onwards, with the project financed through a 60-40 debt-equity structure.

    04

    Regulated Market Entry & European Business

    NGL Fine Chem has secured 3 CEPs and 5 DMF filings, with 5 customers onboarded in the EU market. While EU sales from existing plants are expected to be INR25-30 crores in the current year, significant ramp-up takes 2-3 years. The company plans to file for US FDA approval by the Oct-Dec quarter of 2025, with approval anticipated in 2027. Entry into regulated markets is expected to bring an additional 10-15% margin.

    05

    Product Portfolio & Competitive Landscape

    The company's business is 95% veterinary APIs. Fluralaner, a product that went off-patent in March, is performing well, with NGL Fine Chem being the sole Indian manufacturer. Afoxolaner, another large molecule, is still under patent, with commercial sales expected post-2028. The company is also developing products for the companion animal segment, which currently represents a nascent part of its business.

    06

    Geopolitical & Currency Headwinds

    Geopolitical tensions, specifically the India-Pakistan conflict, resulted in zero sales to Pakistan for the current year, down from INR15 crores last year. Additionally, indirect business to African markets (where customers re-export NGL products) faced slow realizations due to currency availability issues, particularly a lack of US dollars for imports, further impacting the company's business.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.